

Press release  
Gothenburg, Sweden  
17.20 p.m. CET, January 9, 2020

## CELLINK is carrying out stock split (4:1)

*January 13, 2020 is the record date for the split (4:1) as decided by the AGM December 18, 2019.*

The AGM has decided to carry out the stock split, where each existing share is divided into four new shares. The record date is January 13, 2020.

The number of shares after splitting will be 38,984,776; 1,500,000 series A shares and 37,484,776 series B shares. The quota value will amount to 0.025 kronor. As a result of the stock split, shares will receive new ISIN codes. The new ISIN code for B shares is SE0013647385.

The last trading day for B shares with the old ISIN code before the split is January 9, 2020 and the first trading day after the split with the new ISIN code is January 10, 2020.

The stock split will be carried out automatically through Euroclear Sweden AB; share owners do not need to take any action. Shares received in the stock split are expected to be registered in shareholders' security accounts January 14, 2020.

**For more information, please contact:**

Erik Gatenholm, CEO  
EU: +46 73 267 00 00  
US: +1 (650) 515 5566  
Email: [eg@cellink.com](mailto:eg@cellink.com)

Gusten Danielsson, CFO  
EU: +46 70 991 86 04  
US: +1 (857) 332 2138  
Email: [gd@cellink.com](mailto:gd@cellink.com)

**About CELLINK**

CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit [www.cellink.com](http://www.cellink.com) to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company's certified adviser, available by phone at +46 846 383 00 and by email at [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).